Brief: Jcr Pharmaceuticals Receives Approval To Start Global Phase I/Ii Clinical Trial For Jr-441 For Treatment Of Mucopolysaccharidosis Type Iii A
11/07/2023 08:03
JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS RECEIVES APPROVAL TO START GLOBAL
PHASE I/II
CLINICAL TRIAL FOR JR-441 FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS
TYPE III A
Source text for Eikon: ID:nTSsk7f12c
Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results